OR WAIT null SECS
Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses her transition from being a physician to working in pharma, new technologies in reproductive health for men and women, as well as access limitations in fertility treatment.
There has been a lot of discussion surrounding reproductive health and women’s rights in recent months. While there are questions about what access will be available to individuals assigned female at birth, there arealso a lot of new technologies within reproductive health and fertility care.When these topics are raised, many think of women’s health. However, there have been developments in therapeutic options for men as well.
In this episode of the Pharm Exec Podcast, Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, speaks with Meg Rivers, managing editor, about:
Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, is responsible for U.S. clinical development, medical affairs, pharmacovigilance, project planning, and regulatory affairs at Ferring Pharmaceuticals U.S. Garner has nearly 30 years of experience in the medical industry. Prior to joining Ferring in 2022, she held chief medical officer roles for ObsEva, a biotechnology company focused on women’s health, and Agile Therapeutics, a women’s healthcare company. Earlier, she held leadership roles in medical affairs at Myriad Genetics Laboratories and clinical development at Abbott Laboratories and Merck Research Laboratories. Garner also holds a medical degree from Harvard Medical School and has practiced in obstetrics, gynecology, gynecologic oncology, and internal medicine at Brigham and Women’s Hospital and Massachusetts General Hospital. In addition, she holds a master’s degree in public health from Harvard’s T.H. Chan School of Public Health and a bachelor’s degree from Mount Holyoke College in Massachusetts.
The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.